Thymoquinone as an anticancer agent: Evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo

Fundamental and Clinical Pharmacology

Volumn 27, Issue 5, 2013, Pages 557-569

  Attoub, Samir ^a   Sperandio, Olivier ^b   Raza, Haider ^a   Arafat, Kholoud ^a   Al Salam, Suhail ^a   Al Sultan, Mahmood Ahmed ^a   Al Safi, Maha ^a   Takahashi, Takashi ^c   Adem, Abdu ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b INSERM   (France)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA damage; Invasion; Lung breast cancer; Thymoquinone; Tumor growth; Viability

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CISPLATIN; CYTOCHROME C; HISTONE DEACETYLASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; THYMOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

DNA DAMAGE; INVASION; LUNG & BREAST CANCER; THYMOQUINONE; TUMOR GROWTH; VIABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881543265     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01056.x     Document Type: Article

References (39)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55 74-108.
2. Gali-Muhtasib H., Roessner A., Schneider-Stock R. Thymoquinone: a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol. (2006) 38 1249-1253.
3. Woo C.C., Kumar A.P., Sethi G., Tan K.H. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem. Pharmacol. (2011) 83 443-451.
4. Gali-Muhtasib H., Diab-Assaf M., Boltze C., et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int. J. Oncol. (2004) 25 857-866.
5. Rooney S., Ryan M.F. Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res. (2005) 25 2199-2204.
6. Gurung R.L., Lim S.N., Khaw A.K., Soon J.F., Shenoy K., Mohamed Ali S. et al. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS ONE (2010) 5 e12124.
7. Kozaki K., Miyaishi O., Tsukamoto T., Tatematsu Y., Hida T., Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. (2000) 60 2535-2540.
8. Raza H., Prabu S.K., Robin M.A., Avadhani N.G. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: tissue-specific variations and roles in oxidative stress. Diabetes (2004) 53 185-194.
9. Raza H., John A. 4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-transferase A4-4 and cytochrome P450 2E1 in PC12 cells. Toxicol. Appl. Pharmacol. (2006) 216 309-318.
10. Li H., Gao Z., Kang L., Zhang H., Yang K., Yu K. et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res. (2006) 34 W219-W224.
11. Gao Z., Li H., Zhang H., Liu X., Kang L., Luo X. et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics (2008) 9 104.
12. Sethi G., Ahn K.S., Aggarwal B.B. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. (2008) 6 1059-1070.
13. Worthen D.R., Ghosheh O.A., Crooks P.A. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res. (1998) 18 1527-1532.
14. Shoieb A.M., Elgayyar M., Dudrick P.S., Bell J.L., Tithof P.K. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int. J. Oncol. (2003) 22 107-113.
15. El-Mahdy M.A., Zhu Q., Wang Q.E., Wani G., Wani A.A. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J. Cancer (2005) 117 409-417.
16. Banerjee S., Kaseb A.O., Wang Z., Kong D., Mohammad M., Padhye S. et al. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. (2009) 69 5575-5583.
17. Yi T., Cho S.G., Yi Z., Pang X., Rodriguez M., Wang Y. et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. (2008) 7 1789-1796.
18. Li F., Rajendran P., Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br. J. Pharmacol. (2010) 161 541-554.
19. Arafa e.-S., Zhu Q., Shah Z.I., Wani G., Barakat B.M., Racoma I. et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat. Res. (2011) 706 28-35.
20. El-Najjar N., Chatila M., Moukadem H., Vuorela H., Ocker M., Gandesiri M. et al. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis (2010) 15 183-195.
21. Xu N., Hegarat N., Black E.J., Scott M.T., Hochegger H., Gillespie D.A. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J. Cell Biol. (2010) 190 297-305.
22. Gali-Muhtasib H., Kuester D., Mawrin C., Bajbouj K., Diestel A., Ocker M. et al. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res. (2008) 68 5609-5618.
23. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer (2005) 5 876-885.
24. Rooney S., Ryan M.F. Modes of action of alpha-hederin and thymoquinone, active constituents of Nigella sativa, against HEp-2 cancer cells. Anticancer Res. (2005) 25 4255-4259.
25. Wesierska-Gadek J., Gueorguieva M., Wojciechowski J., Tudzarova-Trajkovska S. In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment. J. Cell. Biochem. (2004) 93 774-787.
26. Woo C.C., Loo S.Y., Gee V., Yap C.W., Sethi G., Kumar A.P. et al. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. Biochem. Pharmacol. (2011) 82 464-475.
27. Kolli-Bouhafs K., Boukhari A., Abusnina A., Velot E., Gies J.P., Lugnier C. et al. Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest. New Drugs (2011).
28. Gali-Muhtasib H., Ocker M., Kuester D., Krueger S., El-Hajj Z., Diestel A. et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J. Cell Mol. Med. (2008) 12 330-342.
29. Al-Ali A., Alkhawajah A.A., Randhawa M.A., Shaikh N.A. Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J. Ayub Med. Coll. Abbottabad (2008) 20 25-27.
30. Al-Amri A.M., Bamosa A.O. Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. Shiraz E-Med. J. (2009) 10 107-111.
31. Jafri S.H., Glass J., Shi R., Zhang S., Prince M., Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J. Exp. Clin. Cancer Res. (2010) 29 87.
32. Kaseb A.O., Chinnakannu K., Chen D., Sivanandam A., Tejwani S., Menon M. et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. (2007) 67 7782-7788.
33. Badary O.A., Nagi M.N., al-Shabanah O.A., al-Sawaf H.A., al-Sohaibani M.O., al-Bekairi A.M. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can. J. Physiol. Pharmacol. (1997) 75 1356-1361.
34. Nagi M.N., Mansour M.A. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol. Res. (2000) 41 283-289.
35. Ferraldeschi R., Baka S., Jyoti B., Faivre-Finn C., Thatcher N., Lorigan P. Modern management of small-cell lung cancer. Drugs (2007) 67 2135-2152.
36. Lally B.E., Urbanic J.J., Blackstock A.W., Miller A.A., Perry M.C. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist (2007) 12 1096-1104.
37. Chehl N., Chipitsyna G., Gong Q., Yeo C.J., Arafat H.A. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) (2009) 11 373-381.
38. Hoeft B., Linseisen J., Beckmann L., Müller-Decker K., Canzian F., Hüsing A. et al. Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis (2010) 31 466-472.
39. Banerjee S., Azmi A.S., Padhye S., Singh M.W., Baruah J.B., Philip P.A. et al. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm. Res. (2010) 27 1146-1158.